Substance P (NK1) Receptor Neurons

Substance P (NK1) Receptor Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Substance P (NK1) Receptor Neurons</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000197](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)</td>
</tr>
<tr>
<td class="label">Receptor Type</td>
<td>NK1 (TACR1)</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Tachykinin (GPCR)</td>
</tr>
<tr>
<td class="label">Signaling Mechanism</td>
<td>Gq protein-coupled, activates phospholipase C</td>
</tr>
<tr>
<td class="label">Primary Ligand</td>
<td>Substance P (SP)</td>
</tr>
<tr>
<td class="label">Primary Brain Locations</td>
<td>Amygdala, hippocampus, striatum, nucleus accumbens, spinal cord dorsal horn</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">NK1 antagonists</td>
<td>Clinical trials</td>
</tr>
<tr>
<td class="label">Substance P analogs</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Experimental</td>
</tr>
</table>

Substance P (NK1) Receptor Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Substance P (NK1) Receptor Neurons</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000197](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)</td>
</tr>
<tr>
<td class="label">Receptor Type</td>
<td>NK1 (TACR1)</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Tachykinin (GPCR)</td>
</tr>
<tr>
<td class="label">Signaling Mechanism</td>
<td>Gq protein-coupled, activates phospholipase C</td>
</tr>
<tr>
<td class="label">Primary Ligand</td>
<td>Substance P (SP)</td>
</tr>
<tr>
<td class="label">Primary Brain Locations</td>
<td>Amygdala, hippocampus, striatum, nucleus accumbens, spinal cord dorsal horn</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">NK1 antagonists</td>
<td>Clinical trials</td>
</tr>
<tr>
<td class="label">Substance P analogs</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Experimental</td>
</tr>
</table>

Substance P (NK1) Receptor Neurons represent a specialized population of neurons expressing the NK1 receptor, the high-affinity receptor for Substance P (SP), a member of the tachykinin neuropeptide family. These neurons are widely distributed throughout the central and peripheral nervous system and play critical roles in pain transmission, neuroinflammation, mood regulation, and autonomic function. Recent research has increasingly implicated Substance P and NK1 receptor signaling in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD)[@substance2020][@substance2020a].

Overview

Substance P (NK1) Receptor Neurons are neurons expressing the NK1 receptor, a member of the Tachykinin receptor family (also known as TACR1). These neurons are widely distributed throughout key brain regions including the amygdala, hippocampus, basal ganglia, striatum, and spinal cord dorsal horn["@distribution1994"]. The NK1 receptor is a G protein-coupled receptor (GPCR) that primarily signals through Gq proteins, activating phospholipase C (PLC) and leading to downstream effects including calcium mobilization, protein kinase C (PKC) activation, and gene transcription modulation["@signal1991"].

<!-- multi-taxonomy-enrichment -->

Multi-Taxonomy Classification

Taxonomy Database Cross-References

External Database Links

• [Cell Ontology (CL:0000197)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)
• [OBO Foundry (CL:0000197)](http://purl.obolibrary.org/obo/CL_0000197)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [Human Cell Atlas](https://www.humancellatlas.org/)

Receptor Properties

Function

Neurotransmission

Substance P acts as a neuropeptide neurotransmitter and neuromodulator in the mammalian nervous system. Unlike classical amino acid neurotransmitters, Substance P is synthesized in the cell body and transported to synaptic terminals where it is released upon neuronal activation. NK1 receptor-expressing neurons participate in:

Signaling Pathway

The NK1 receptor signals through Gq protein-coupled receptor activation:

This mechanism allows rapid modulatory responses depending on the cellular context and co-expression of other receptors.

Role in Neurodegenerative Diseases

Alzheimer's Disease

Substance P and NK1 receptor signaling have been implicated in several key aspects of Alzheimer's disease pathogenesis:

Parkinson's Disease

In Parkinson's disease, Substance P neurons are particularly relevant due to their localization in key affected regions:

Therapeutic Implications

The NK1 receptor represents a potential therapeutic target for neurodegenerative diseases:

Clinical Considerations

• Blood-brain barrier penetration: Most NK1 antagonists have good BBB penetration
• Side effects: Historical NK1 antagonists (aprepitant) were primarily developed for chemotherapy-induced nausea
• Combination potential: May be combined with anti-inflammatory or neuroprotective agents

See Also

• [Neuroinflammation Mechanisms
• [Tachykinin Signaling](/genes/gnal)
• [Amygdala in Neurodegeneration](/brain-regions/amygdala)
• [Hippocampus in Alzheimer's Disease](/diseases/alzheimers-disease)

Pathway Diagram

The following diagram shows the key molecular relationships involving Substance P (NK1) Receptor Neurons discovered through SciDEX knowledge graph analysis: